A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants with Early AD

Eligibility Criteria

• 1. Diagnosis of AD according to the 2024 National Institute on Aging and Alzheimer's Association criteria.
• 2. Male or female, aged 55 - 85 years.
• 3. MMSE 21-28 at screening and baseline.
• 4. CDR global score=0.5 or 1, with memory box score at least 0.5 at screening and baseline.
• 5. Positive for amyloid beta as defined by plasma p-tau217 level at screening.
• 6. Neuroimaging (MRI) consistent with the clinical diagnosis of AD and without findings of significant exclusionary abnormalities (see exclusion criteria # 4). A historical MRI, up to 1 year prior to screening, may be used as long as there have been no interval clinical neurologic events that may suggest a change in the MRI scan.
• 7. Have a study partner who will provide written informed consent to participate, is in frequent contact with the participant (defined as at least 10 hours per week) and will accompany the participant on study visits at designated times.
• 8. Female participants of childbearing potential\* must have a negative urine pregnancy test at screening, must be non-lactating and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for one month after the last dose of trial treatment, such as:
• * Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
• * Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
• * Intrauterine device (IUD),
• * Intrauterine hormone-releasing system (IUS),
• * Bilateral tubal occlusion,
• * Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant. If not, an additional highly effective method of contraception should be used),
• * Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant).
• * Non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start.
• 9. Male participants must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male participants must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:
• * Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
• * Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
• * IUD,
• * IUS,
• * Bilateral tubal occlusion.
• 10. General cognition and functional performance sufficiently preserved that the subject can provide written informed consent.
• 11. No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the Columbia Suicide Severity Rating Scale.
• 12. Stability of permitted medications for at least 4 weeks prior to screening. Refer to Concomitant Medications section for details on prohibited and permitted medications.
• * Cholinesterase inhibitors and/or memantine medication,
• * Anticonvulsant medications used for epilepsy or mood stabilization, or neuropathic pain indications, and have not had a breakthrough seizure in 3 years prior to screening
• * Mood-stabilizing psychotropic agents including, but not limited to, lithium.
• 13. Adequate visual and hearing ability (physical ability to perform all the study assessments).
• 14. Participants previously exposed to buntanetap can still be included in the study after a 28-day wash out period.
• 1. Has a history of psychiatric disorder such as schizophrenia, bipolar disorder, or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), unless they are stable on treatment or no longer need treatment. Mild depression or history of depression that is stable on treatment with selective serotonin reuptake inhibitors (SSRI), serotonin and norepinephrine reuptake inhibitors (SNRI) or other anti-depression medication (e.g. Wellbutrin) at a stable dose is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.
• 2. Has non-AD dementia, such as vascular dementia, Lewy body dementia, frontotemporal disease, PD dementia, B12 and thyroid deficiency caused dementia.
• 3. History of a seizure disorder, if stable on medication is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.
• 4. Screening MRI (or historical MRI, if applicable) of the brain indicative of significant abnormality, including, but not limited to, prior hemorrhage or infarct \> 1 cm3, \> 3 lacunar infarcts, cerebral contusion, encephalomalacia, aneurysm, vascular malformation, subdural hematoma, hydrocephalus, space-occupying lesion (e.g., abscess or brain tumor such as meningioma unless they are documented and stable).
• 5. Has a history or current evidence of long QT syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 450 ms for men and ≥ 460 ms for women ((in the absence of a bundle branch block), or torsades de pointes.
• 6. Has bradycardia (\<50 bpm) or tachycardia (\>100 bpm) on the ECG at screening and deemed medically significant by the PI.
• 7. Has uncontrolled Type-1 or Type-2 diabetes. A participant with hemoglobin subunit alpha 1c (HbA1c) levels up to 7.5% can be enrolled if the PI believes the participant's diabetes is under control.
• 8. Has clinically significant renal (Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) \<60 mL/min/BSA (body surface area) or hepatic impairment (alkaline phosphatase (ALP) \> 2.0 ULN and/or total bilirubin \> 2.0 ULN).
• 9. Has any clinically significant abnormal laboratory values. Participants with liver function tests (aspartate aminotransferase (AST) or alanine aminotransferase (ALT)) greater than twice the upper limit of normal will be excluded.
• 10. Is at imminent risk of self-harm, based on clinical interview and responses on the C- SSRS, or of harm to others in the opinion of the PI. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g., positive response to items 4 or 5 in assessment of suicidal ideation on the C-SSRS) in the past 2 months, or suicidal behavior in the past 6 months.
• 11. Has cancer or has had a malignant tumor within the past year, except participants who underwent potentially curative therapy with no evidence of recurrence (participants with stable untreated cancer are not excluded).
• 12. Alcohol / Substance use disorder, moderate to severe, in the last 5 years according to the most current version DSM.
• 13. Participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken.
• 14. Participants with learning disability or developmental delay.
• 15. Participants whom the PI deems to be otherwise ineligible.
• 16. Participants with a known allergy to the investigational drug or any of its components.
• * Silicified Microcrystalline Cellulose
• * Dibasic Calcium Phosphate Dihydrate
• * Mannitol
• * Stearic Acid
• * Hypromellosee (capsule shells structure)
• * Titanium dioxide (opacifier of the capsule shells)
• 17. Participant is currently pregnant, breast-feeding, and/or lactating.
• 18. Participant is currently taking strong and moderate CYP3A4 inhibitors and/or inducers. Refer to Concomitant Medications section below for details on prohibited and permitted medications.
• 19. Participants with uncontrolled hypertension (systolic \>160mm Hg and/or diastolic \>95mm Hg) or hypotension (systolic \<90mm Hg and/or diastolic \<60 mm Hg) and deemed medically significant by the PI.